Price
CHART BY
Frequently asked questions
What is Ocugen's market capitalization?
The market capitalization of Ocugen is $447.63M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Ocugen?
Ocugen's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.255. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Ocugen's stock?
Currently, 6 analysts cover Ocugen's stock, with a consensus target price of $12.17. Analyst ratings provide insights into the stock's expected performance.
What is Ocugen's revenue over the trailing twelve months?
Over the trailing twelve months, Ocugen reported a revenue of $4.58M.
What is the EBITDA for Ocugen?
Ocugen's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$67.17M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Ocugen?
Ocugen has a free cash flow of -$61.02M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Ocugen have, and what sector and industry does it belong to?
Ocugen employs approximately 116 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Ocugen's shares?
The free float of Ocugen is 333.38M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $447.63M
- EPS (TTM)
- -$0.255
- Free Float
- 333.38M
- Revenue (TTM)
- $4.58M
- EBITDA (TTM)
- -$67.17M
- Free Cashflow (TTM)
- -$61.02M
Pricing
- 1D span
- $1.315$1.387
- 52W span
- $1.005$2.72
Analyst Ratings
The price target is $12.17 and the stock is covered by 6 analysts.
Buy
6
Hold
0
Sell
0
Information
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
- Employees
- 116
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- OCGN
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet